Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With Alzheimer's Disease Receiving Standard-of-care

NCT03456349 is registered in ClinicalTrials.gov with Nxera Pharma UK Limited as lead sponsor.

NCT NCT03456349
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03456349 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study to Determine the Safety and Tolerability of HTL0018318 in Subjects With Alzheimer's Disease Receiving Standard-of-care
Lead sponsor
Nxera Pharma UK Limited
Phase
Phase 1
Overall status
Completed
Start date
November 10, 2017
Completion date
July 16, 2018
Enrollment
60 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease